Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
2007-07-03
2007-07-03
Foley, Shanon (Department: 1642)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
C424S469000, C556S137000
Reexamination Certificate
active
10918762
ABSTRACT:
The subject invention concerns methods for inhibition of STAT biological functions using platinum complexes.
REFERENCES:
patent: 5849790 (1998-12-01), Palmer et al.
patent: 6511676 (2003-01-01), Boulikas
patent: 2002/0035243 (2002-03-01), Imfeld et al.
patent: 2002/0120100 (2002-08-01), Bonny
patent: 2003/0032594 (2003-02-01), Bonny
Tukson et al. (Oncogene 2000: 19; 6613-6626).
Zheligovskaya et al. Vestnik Moskovskogo Universiteta. Khimiya, 1970, pp. 32-37, vol. 11, No. 1, XP009041901.
U.S. Appl. No. 10/918,769, Kay et al.
U.S. Appl. No. 11/030,567, Kay et al.
Akira, S. “Roles of STAT3 Defined by Tissue-Specific Gene Targeting”,Oncogene, 2000, pp. 2607-2611, vol. 19.
Ardizzoni, A. et al., “The Combination of Etoposide and Cisplatin in Non-Small-Cell Lung Cancer (NSCLC)”,Ann. Oncol., 1999, pp. S13-17, vol. 10.
Bowman, T. et al. “STATs in Oncogenesis”,Oncogene, 2000, pp. 2474-2488, vol. 19.
Bowman, T. et al. “Stat3-Mediated Myc Expression is Required for Src Transformation and PDGF-Induced Mitogenesis”,Proc Natl. Acad. Sci. USA, 2000, pp. 7319-7324, vol. 98, No. 3.
Bromberg, J. F. et al. “Transcriptionally Active Stat1 is Required for the Antiproliferative Effects of Both Interferon Alpha and Interferon Gamma”,Proc. Natl. Acad. Sci. USA, 1996, pp. 7673-7678, vol. 93.
Bromberg, J. F. et al. “Stat3 Activation is Required for Cellular Transformation by V-src”, Mol. Cell. Biol., 1998, pp. 2553-2558, vol. 18, No. 5.
Bromberg, J. F. et al. “Stat3 as an Oncogene”,Cell, 1999, pp. 295-303, vol. 98.
Catlett-Falcone, R. et al. “Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells”,Immunity, 1999, pp. 105-115, vol. 10.
Catlett-Falcone, R. et al. “STAT Proteins as Novel Targets for Cancer Therapy”,Curr. Opin. Oncol., 1999, pp. 490-496, vol. 11.
Coffer, P. J. et al. “The Role of STATs in Myeloid Differentiation and Leukemia”,Oncogene, 2000, pp. 2511-2522, vol. 19.
Darnell, J. E., Jr. et al. “Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins”,Science, 1994, pp. 1415-1421, vol. 264, No. 5164.
Darnell, J. E., Jr. “STATs and Gene Regulation”,Science, 1997, pp. 1630-1635, vol. 277.
Epling-Burnette, P. K. et al. “Inhibition of STAT3 Signaling Leads to Apoptosis of Leukemic Large Granular Lymphocytes and Decreased Mcl-1 Expression”,J. Clin. Invest, 2001, pp. 351-361, vol. 107, No. 3.
Fukada, T. et al. “Two Signals are Necessary for Cell Proliferation Induced by a Cytokine Receptor gp130: Involvement of STAT3 in Anti-Apoptosis”,Immunity, 1996, pp. 449-460, vol. 5.
Garcia, R. et al. “Constitutive Activation of Stat3 in Fibroblasts Transformed by Diverse Oncoproteins and in Breast Carcinoma Cells”,Cell Growth Diff., 1997, pp. 1267-1276, vol. 8.
Garcia, R. et al. “Activation of STAT Transcription Factors in Oncogenic Tyrosine Kinase Signaling”,J. Biomed. Sci., 1998, pp. 79-85, vol. 5.
Garcia, R. et al. “Constitutive Activation of Stat3 by the Src and JAK Tyrosine Kinases Participates in Growth Regulation of Human Breast Carcinoma Cells”,Oncogene, 2001, pp. 2499-2513, vol. 20.
Gouilleux, F. et al. “Prolactin and Interleukin-2 Receptors in T Lymphocytes Signal Through A MGF-STAT5-like Transcription Factor”,Endocrinology, 1995, pp. 5700-5708, vol. 136, No. 12.
Grandis, J. R. et al. “Requirement of Stat3 but Not Stat1 Activation for Epidermal Growth Factor Receptor-Mediated Cell Growth In Vitro”,J. Clin. Invest., 1998, pp. 1385-1392, vol. 102, No. 7.
Grandis, J. R. et al. “Constitutive Activation of Stat3 Signaling Abrogates Apoptosis in Squamous Cell CarcinogenesisIn Vivo”, Proc. Natl. Acad. Sci. USA, 2000, pp. 4227-4232, vol. 97, No. 8.
Grandis, J. R. et al. “Epidermal Growth Factor Receptor—Mediated Stat3 Signaling Blocks Apoptosis in Head and Neck Cancer”,Laryngoscope, 2000, pp. 868-874, vol. 110.
Hirano, T. et al. “Roles of STAT3 in Mediating the Cell Growth, Differentiation and Survival Signals Relayed Through the IL-6 Family of Cytokine Receptors”,Oncogene, 2000, pp. 2548-2556, vol. 19.
Horiguchi, A. et al. “STAT3, but Not ERKs, Mediates the IL-6-Induced Proliferation of Renal Cancer Cells, ACHN and 769P”,Kidney Int, 2002, pp. 926-938, vol. 61.
Johnson, P. J. et al. “Overexpressed pp60c-sncCan Induce Focus Formation Without Complete Transformation of NIH 3T3 Cells”,Mol. Cell. Biol., 1985, pp. 1073-1083, vol. 5, No. 5.
Kotenko, S. V. et al. “Jak-Stat Signal Transduction Pathway Through the Eyes of Cytokine Class II Receptor Complexes”,Oncogene, 2000, pp. 2557-2565, vol. 19.
Kunisada, K. et al. “Activation of gp130 Transduces Hypertrophic Signals Via STAT3 in Cardiac Myocytes”,Circulation, 1998, pp. 346-352, vol. 98.
Lin, T. S. et al. “STAT Signaling in the Pathogenesis and Treatment of Leukemias”,Oncogene, 2000, pp. 2496-2504, vol. 19.
Nielsen, M. et al. “Constitutive Activation of a Slowly Migrating Isoform of Stat3 in Mycosis Fungoides: Tyrphostin AG490 Inhibits Stat3 Activation and Growth of Mycosis Fungoides Tumor Cell Lines”,Proc. Natl. Acad. Sci. USA, 1997, pp. 6764-6769, vol. 94.
Nielsen, M. et al. “Inhibition of Constitutively Activated Stat3 Correlates with Altered Bcl-2/Bax Expression and Induction of Apoptosis in Mycosis Fungoides Tumor Cells”,Leukemia, 1999, pp. 735-738, vol. 13.
Nitiss, J. L. “A Copper Connection to the Uptake of Platinum Anticancer Drugs”,Proc. Natl. Acad. Sci. USA, 2002, pp. 13963-13965, vol. 99, No. 22.
Persons, D. L. et al. “Cisplatin-Induced Activation of Mitogen-Activated Protein Kinases in Ovarian Carcinoma Cells: Inhibition of Extracellular Signal-Regulated Kinase Activity Increases Sensitivity to Cisplatin”,Clin. Cancer Res., 1999, pp. 1007-1014, vol. 5.
Sanchez-Perez, I. et al. “Cisplatin Induces a Persistent Activation of JNK That is Related to Cell Death”,Oncogene, 1998, pp. 533-540, vol. 16.
Schindler, C. et al. “Transcriptional Responses to Polypeptide Ligands: The JAK-STAT Pathway”,Annu. Rev. Biochem., 1995, pp. 621-651, vol. 64.
Seidel, H. M. et al. “Spacing of Palindromic Half Sites as a Determinant of Selective STAT (Signal Transducers and Activators of Transcription) DNA Binding and Transcriptional Activity”,Proc. Natl. Acad. Sci. USA, 1995, pp. 3041-3045, vol. 92.
Smithgall, T. E. et al. “Control of Myeloid Differentiation and Survival by Stats”,Oncogene, 2000, pp. 2612-2618, vol. 19.
Song, J. I. et al. “STAT Signaling in Head and Neck Cancer”,Oncogene, 2000, pp. 2489-2495, vol. 19.
Stark, G. R. et al. “How Cells Respond to Interferons”,Annu. Rev. Biochem, 1998, pp. 227-264, vol. 67.
Turkson, J. et al. “Stat3 Activation by Src Induces Specific Gene Regulation and is Required for Cell Transformation”,Mol. Cell. Biol., 1998, pp. 2545-2552, vol. 18, No. 5.
Turkson, J. et al. “Requirement for Ras/Rac1-Mediated p38 and c-Jun N-Terminal Kianse Signaling in Stat3 Transcriptional Activity Induced by the Src Oncoprotein”,Mol. Cell. Biol., 1999, pp. 7519-7528, vol. 19, No. 11.
Turkson, J. et al. “STAT Proteins: Novel Molecular Targets for Cancer Drug Discovery”,Oncogene, 2000, pp. 6613-6626, vol. 19.
Turkson, J. et al. “Phosphotyrosyl Peptides Block Stat3-Mediated DNA Binding Activity, Gene Regulation, and Cell Transformation”,J. Biol. Chem., 2001, pp. 45443-45455, vol. 276, No. 48.
Wagner, B. J. et al. “The SIF Binding Element Confers sis/PDGF Inducibility Onto the c-fos Promoter”,EMBO J., 1990, pp. 4477-4484, vol. 9, No. 13.
Yu, C. L. et al. “Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein”,Science,
Jove Richard
Kay Heidi
Palmer Jay W.
Turkson James
Yu Hua
Fetterolf Brandon
Foley Shanon
Saliwanchik Lloyd & Saliwanchik
University of South Florida
LandOfFree
Methods for inhibiting tumor cell proliferation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting tumor cell proliferation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting tumor cell proliferation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3791101